MVCD5
MCID: MCR115
MIFTS: 67

Microvascular Complications of Diabetes 5 (MVCD5)

Categories: Cardiovascular diseases, Eye diseases, Genetic diseases, Nephrological diseases, Neuronal diseases

Aliases & Classifications for Microvascular Complications of Diabetes 5

MalaCards integrated aliases for Microvascular Complications of Diabetes 5:

Name: Microvascular Complications of Diabetes 5 57 74 29 13 6 38 40
Diabetic Retinopathy 12 37 29 55 44 15 17 72 33
Retinopathy, Diabetic 57 75
Diabetic Nephropathy 74 72
Mvcd5 57 74
Microvascular Complications of Diabetes, Susceptibility to, 5 57
Retinopathy, Diabetic, Susceptibility to 57
Retinal Abnormality - Diabetes-Related 12

Classifications:



External Ids:

Disease Ontology 12 DOID:8947
KEGG 37 H01457
ICD9CM 35 362.0
NCIt 50 C34538
SNOMED-CT 68 4855003
ICD10 33 H36.0
MedGen 42 C2674665
UMLS 72 C0011881 C0011884

Summaries for Microvascular Complications of Diabetes 5

KEGG : 37
Diabetic retinopathy (DR), one of the most common vascular complication of diabetes, is the leading cause of visual deficits and blindness around the world. The development of DR is divided into two stages: in the early stages, also called as nonproliferative stage, it is asymptomatic because the signs are not visible to the eye. however, some defects including microaneurysms, intraretinal hemorrhaging, narrowing or blocked retinal blood vessels can be seen by detection; in the second stage, known as proliferative diabetic retinopathy, where neovascularization appears at the back of the eye and extend into the vitreous of the eye, and these new blood vessels are fragile. If they leak blood, the bleeding causes shrinkage of the retina, leading to retinal detachment, and ultimately to blindness. It has been reported that vascular endothelial growth factor A, angiotensin-converting enzyme, paraoxonase, erythropoietin are associated with DR development and progression.

MalaCards based summary : Microvascular Complications of Diabetes 5, also known as diabetic retinopathy, is related to microvascular complications of diabetes 3 and microvascular complications of diabetes 1. An important gene associated with Microvascular Complications of Diabetes 5 is PON1 (Paraoxonase 1), and among its related pathways/superpathways are AGE-RAGE signaling pathway in diabetic complications and HIF-1 signaling pathway. The drugs Pioglitazone and Simvastatin have been mentioned in the context of this disorder. Affiliated tissues include Eye and Eye, and related phenotypes are cardiovascular system and homeostasis/metabolism

UniProtKB/Swiss-Prot : 74 Microvascular complications of diabetes 5: Pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis.

Wikipedia : 75 Diabetic retinopathy, also known as diabetic eye disease, is a medical condition in which damage occurs... more...

More information from OMIM: 612633 PS603933

Related Diseases for Microvascular Complications of Diabetes 5

Diseases in the Microvascular Complications of Diabetes 5 family:

Microvascular Complications of Diabetes 1 Microvascular Complications of Diabetes 2
Microvascular Complications of Diabetes 3 Microvascular Complications of Diabetes 4
Microvascular Complications of Diabetes 6 Microvascular Complications of Diabetes 7

Diseases related to Microvascular Complications of Diabetes 5 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 674)
# Related Disease Score Top Affiliating Genes
1 microvascular complications of diabetes 3 33.1 INS ALB ACE
2 microvascular complications of diabetes 1 32.3 VEGFA SERPINF1 INS IGF1 ICAM1 FLT1
3 maturity-onset diabetes of the young, type 1 32.1 SERPINE1 INS ALB ACE
4 rubeosis iridis 31.7 VEGFA INS IGF1
5 lipid metabolism disorder 31.5 SERPINE1 INS ACE
6 retinal vein occlusion 31.4 VEGFA SERPINF1 SERPINE1
7 autonomic neuropathy 31.3 INS ALB AKR1B1
8 diabetes mellitus, noninsulin-dependent 31.3 SERPINE1 PON1 NOS3 INS IGF1 ALB
9 peripheral nervous system disease 31.2 INS ALB AKR1B1
10 diabetic cataract 31.2 VEGFA SERPINF1 AKR1B1
11 macular dystrophy, dominant cystoid 31.2 VEGFA SERPINF1 PRKCB
12 hypertensive nephropathy 31.2 VEGFA ALB ACE
13 diabetic polyneuropathy 31.1 VEGFA AKR1B1 AGER
14 background diabetic retinopathy 31.0 VEGFA INS ANGPT2 ALB
15 peripheral artery disease 30.9 VEGFA NOS3 ACE
16 severe nonproliferative diabetic retinopathy 30.9 VEGFA INS ALB
17 macular holes 30.7 VEGFA SERPINF1 ANGPT2
18 retinal artery occlusion 30.7 VEGFA SERPINE1 ACE
19 eclampsia 30.6 PGF FLT1 ALB
20 proteasome-associated autoinflammatory syndrome 1 30.6 INS ICAM1 ALB
21 coronary artery anomaly 30.6 SERPINE1 PON1 NOS3 ACE
22 coronary heart disease 1 30.6 SERPINE1 PON1 NOS3 INS ACE
23 atherosclerosis susceptibility 30.6 SERPINE1 PON1 NOS3 INS ICAM1
24 hyperglycemia 30.5 PRKCB NOS3 INS IGF1 ALB AKR1B1
25 cerebrovascular disease 30.5 SERPINE1 PON1 INS ICAM1 ACE
26 leukostasis 30.4 VEGFA KDR ICAM1
27 severe pre-eclampsia 30.4 VEGFA PGF ALB
28 pyelonephritis 30.4 PGF ALB ACE
29 pulmonary edema 30.4 NOS3 ICAM1 ACE
30 idiopathic interstitial pneumonia 30.4 VEGFA SERPINE1 ICAM1
31 diabetic neuropathy 30.3 VEGFA INS AKR1B1 ACE
32 kidney disease 30.3 SERPINE1 NOS3 INS ALB AKR1B1 AGER
33 pineal hyperplasia, insulin-resistant diabetes mellitus, and somatic abnormalities 30.3 INS IGF1
34 familial hyperlipidemia 30.3 SERPINE1 PON1 INS
35 arteriosclerosis 30.2 SERPINE1 PON1 INS ICAM1 ACE
36 peripheral vascular disease 30.1 VEGFA SERPINE1 ALB ACE
37 stroke, ischemic 30.1 SERPINE1 PON1 NOS3 MIAT ACE
38 vascular cancer 30.0 VEGFA KDR FLT1 FGF2
39 epileptic encephalopathy, childhood-onset 30.0 VEGFA SERPINE1 KDR ANGPT2
40 body mass index quantitative trait locus 11 29.9 SERPINE1 PON1 NOS3 INS IGF1
41 ischemia 29.9 VEGFA PON1 NOS3 ICAM1 ACE
42 diabetes mellitus, insulin-dependent 29.9 INS IGF1 ALB AKR1B1 ACE
43 exudative vitreoretinopathy 1 29.9 VEGFA TEK KDR IGF1 FLT1 ANGPT2
44 vascular disease 29.9 VEGFA SERPINE1 PON1 NOS3 INS FGF2
45 myeloma, multiple 29.9 VEGFA IGF1 FGF2 ALB
46 coronary stenosis 29.8 SERPINE1 PON1 ICAM1 ALB ACE
47 intermittent claudication 29.8 VEGFA SERPINE1 ANGPT2 ALB ACE
48 sleep apnea 29.7 NOS3 INS IGF1 ICAM1 ACE
49 diabetic macular edema 29.7 VEGFA TEK SERPINF1 PRKCB NOS3 ICAM1
50 hypertension, essential 29.6 SERPINE1 NOS3 INS ALB ACE

Graphical network of the top 20 diseases related to Microvascular Complications of Diabetes 5:



Diseases related to Microvascular Complications of Diabetes 5

Symptoms & Phenotypes for Microvascular Complications of Diabetes 5

Clinical features from OMIM:

612633

MGI Mouse Phenotypes related to Microvascular Complications of Diabetes 5:

46 (show all 18)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.51 ACE AGER ANGPT2 FGF2 FLT1 ICAM1
2 homeostasis/metabolism MP:0005376 10.48 ACE AGER AKR1B1 ALB ANGPT2 FGF2
3 hematopoietic system MP:0005397 10.38 ACE AGER FGF2 FLT1 ICAM1 IGF1
4 growth/size/body region MP:0005378 10.36 ACE AGER AKR1B1 FLT1 ICAM1 IGF1
5 immune system MP:0005387 10.36 ACE AGER ANGPT2 FLT1 ICAM1 IGF1
6 cellular MP:0005384 10.35 AGER ALB ANGPT2 FGF2 FLT1 ICAM1
7 mortality/aging MP:0010768 10.3 ACE AKR1B1 ALB ANGPT2 FGF2 FLT1
8 muscle MP:0005369 10.17 AGER ALB FGF2 FLT1 ICAM1 IGF1
9 integument MP:0010771 10.15 AGER ANGPT2 ICAM1 IGF1 INS KDR
10 nervous system MP:0003631 10.11 FGF2 FLT1 ICAM1 IGF1 INS KDR
11 digestive/alimentary MP:0005381 10.1 ALB ANGPT2 ICAM1 INS NOS3 SERPINF1
12 liver/biliary system MP:0005370 10.02 ACE ALB INS KDR NOS3 SERPINE1
13 neoplasm MP:0002006 10.01 ACE ALB FGF2 ICAM1 IGF1 PGF
14 normal MP:0002873 9.97 AGER ALB FLT1 IGF1 INS KDR
15 renal/urinary system MP:0005367 9.91 ACE AGER AKR1B1 ALB IGF1 INS
16 respiratory system MP:0005388 9.7 ANGPT2 IGF1 KDR NOS3 PGF SERPINE1
17 skeleton MP:0005390 9.61 AGER AKR1B1 FGF2 IGF1 INS KDR
18 vision/eye MP:0005391 9.4 AKR1B1 ANGPT2 FGF2 FLT1 ICAM1 INS

Drugs & Therapeutics for Microvascular Complications of Diabetes 5

Drugs for Microvascular Complications of Diabetes 5 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 574)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
2
Simvastatin Approved Phase 4 79902-63-9 54454
3
Methylcobalamin Approved, Experimental, Investigational Phase 4 13422-55-4
4
Zaleplon Approved, Illicit, Investigational Phase 4 151319-34-5 5719
5
Moxonidine Approved, Investigational Phase 4 75438-57-2 4810
6
Atenolol Approved Phase 4 29122-68-7 2249
7
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
8
Methyldopa Approved Phase 4 555-30-6 38853
9
Clonidine Approved Phase 4 4205-90-7 2803
10
Capsaicin Approved Phase 4 404-86-4 1548943
11
Isosorbide Dinitrate Approved, Investigational Phase 4 87-33-2 6883
12
AT-101 Approved, Investigational Phase 4 90141-22-3, 652-67-5 12597
13
Ranibizumab Approved Phase 4 347396-82-1 459903
14
Bevacizumab Approved, Investigational Phase 4 216974-75-3
15
Tocopherol Approved, Investigational Phase 4 1406-66-2, 54-28-4 14986
16
Copper Approved, Investigational Phase 4 7440-50-8 27099
17
Nepafenac Approved, Investigational Phase 4 78281-72-8 151075
18
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
19
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
20
Dipivefrin Approved Phase 4 52365-63-6 3105
21
Latanoprost Approved, Investigational Phase 4 130209-82-4 5282380 5311221
22
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
23
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
24
Probucol Approved, Investigational Phase 4 23288-49-5 4912
25
Olmesartan Approved, Investigational Phase 4 144689-63-4, 144689-24-7 130881 158781
26
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
27
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
28
Doxazosin Approved Phase 4 74191-85-8 3157
29
Indapamide Approved Phase 4 26807-65-8 3702
30
Atorvastatin Approved Phase 4 134523-00-5 60823
31
Benazepril Approved, Investigational Phase 4 86541-75-5 5362124
32
Nisoldipine Approved Phase 4 63675-72-9 4499
33
Insulin glulisine Approved Phase 4 207748-29-6
34
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
35
Nitric Oxide Approved Phase 4 10102-43-9 145068
36
Bromfenac Approved Phase 4 91714-94-2 60726
37
Insulin Lispro Approved Phase 4 133107-64-9
38
Alprostadil Approved, Investigational Phase 4 745-65-3 5280723 149351
39
Nitroglycerin Approved, Investigational Phase 4 55-63-0 4510
40
Homatropine Approved Phase 4 87-00-3
41
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
42
Febuxostat Approved Phase 4 144060-53-7 134018
43
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
44
Tadalafil Approved, Investigational Phase 4 171596-29-5 110635
45
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
46
Fenofibrate Approved Phase 4 49562-28-9 3339
47
Losartan Approved Phase 4 114798-26-4 3961
48
Enalapril Approved, Vet_approved Phase 4 75847-73-3 5362032 40466924
49
Enalaprilat Approved Phase 4 76420-72-9 6917719
50
Candesartan cilexetil Approved Phase 4 145040-37-5 2540

Interventional clinical trials:

(show top 50) (show all 1164)
# Name Status NCT ID Phase Drugs
1 Panretinal Photocoagulation for Proliferative Diabetic Retinopathy in a Single Session Using Low Fluence Parameters Unknown status NCT01023698 Phase 4
2 Effects of Glatiramer Acetate (Copaxone) in the Nerve Fiber Layer Thickness and Retinal Function in Diabetic Patients After Pan- Retinal Photocoagulation (PRP), a Double- Masked Randomized Clinical Trial. Unknown status NCT00677664 Phase 4 Glatiramer acetate (Copaxone);Mannitol
3 The Effects of Thiazolidinedione on the Diabetic Retinopathy and Nephropathy Unknown status NCT01175486 Phase 4 Actos (Pioglitazone);Acarbose
4 Effect of Aldosterone Antagonism in the Reduction of Albuminuria and Diastolic Disfunction of Patients With Diabetic Nephropathy. Unknown status NCT00870402 Phase 4 Spironolactone;Placebo
5 Effect of Folic Acid, Vitamin B6 and Vitamin B12 in Diabetic Retinopathy Unknown status NCT01921192 Phase 4 Folic Acid, vit B6 and B12;Placebo
6 A Prospective, Multi-center, Randomized, Open-label, Parallel-arm Controlled Study of Treating Type 2 Diabetic Nephropathy (Stage II-IV) With Alfacalcidol and Irbesartan Unknown status NCT03147677 Phase 4 Alfacalcidol;Irbesartan
7 The Effect of Bevacizumab on Peripheral Retinal Changes as Imaged by Wide -Field Fluorescein Angiography in Diabetic Macular Edema Unknown status NCT02096874 Phase 4 Bevacizumab
8 Effect of Doxium on High Sensitivity CRP and Endothelin-1 Serum Levels in Patients With Diabetic Retinopathy Unknown status NCT01382498 Phase 4 Calcium dobesilate (Doxium);Placebo drug
9 Effect of Sarpogrelate On the Nephropathy in Type 2 Diabetes Unknown status NCT01869881 Phase 4 Anplag(Sarpogrelate);Placebo
10 Effect of Intravenous and Oral Therapy With Sulodexide on Albuminuria in Type 2 Diabetic Patients Unknown status NCT01316068 Phase 4 intravenous use of sulodexide followed by oral use;use of sulodexide orally only
11 Clinical Trial Technology Development for the Validation of Surrogate Prognostic Markers in Patients With Diabetic Nephropathy Unknown status NCT01673204 Phase 4 Calcitriol;Placebo
12 Phase 4 Study of Mechanisms of Low Protein Diet Supplemented With Ketoanalogs on Reducing Proteinuria and Maintaining Nutritional Status in Type 2 Diabetic Nephropathy Unknown status NCT01300273 Phase 4
13 Effects of Ranibizumab to Delay or Regression Non-proliferative Diabetic Retinopathy(NPDR) With DME Assessed by Microaneurysm Changes: A Pilot Study Unknown status NCT02834663 Phase 4 Lucentis
14 Safety of Add on Aliskiren to ACEI and ARB Treatment in Type 2 Diabetes With Nephropathy Unknown status NCT00949351 Phase 4 Aliskiren 300mg/d
15 Pilot Study Investigating the Use of Intravitreal Ranibizumab in the Treatment of Vitreous Hemorrhage in Proliferative Diabetic Retinopathy Unknown status NCT01824043 Phase 4 intravitreal ranibizumab injections
16 A Prospective, Randomized, Two Period, With an Intermediate Wash Out Period, Cross-over Study to Compare the Effects of Either Combined Therapy With Ramipril and Clopidogrel or Ramipril Monotherapy on Oxidative Stress, Vascular Inflammation and Endothelial Dysfunction in Patients With Type 2 Diabetes and Diabetic Nephropathy Unknown status NCT01743014 Phase 4 Ramipril;Clopidogrel
17 A Pilot Study to Determine if Intravitreal Injections of Pegaptanib Sodium (Macugen) Given Every 12 Weeks for a Year After an Induction Phase of Three Injections Every 6 Weeks Will Reduce the Progression of Proliferative Diabetic Retinopathy in Patients Without Significant Vitreous Hemorrhage in Comparison to Treatment With Retinal Photocoagulation Alone and After an Induction Phase Unknown status NCT01486771 Phase 4 Macugen ® (pegaptanib sodium)
18 A Prospective, Open-label, Parallel, Controlled Study to Evaluate the Efficacy of Fenofibrate on Microalbuminuria in Hypertriglyceridemic Patients With Type 2 Diabetes on Top of Statin Therapy Unknown status NCT02314533 Phase 4 fenofibrate
19 Three Arm, Prospective, Single-blind, Randomized Study Comparing Ranibizumab Plus Green Diode Laser Versus Ranibizumab Plus Pattern Scan Laser (Pascal) Versus Ranibizumab (Monotherapy) for Proliferative Diabetic Retinopathy. Unknown status NCT02005432 Phase 4 Intravitreal Ranibizumabe;panfotocoagulation (PASCAL);panfotocoagulation (PRP) single shoot (ETDRS)
20 Effects of Fenofibrate on Endothelial Progenitor Cell Levels in Diabetic Patients With Retinopathy. A Randomized Controlled Trial. Unknown status NCT01927315 Phase 4 Fenofibrate 145 mg;Placebo
21 Phase 4 Comparison of the Effects of Bevacizumab Before vs After Pattern Panretinal Photocoagulation Unknown status NCT00804206 Phase 4 bevacizumab;bevacizumab
22 A Prospective, Randomised Controlled Trial of Ranibizumab Pre-treatment in Diabetic Vitrectomy - a Pilot Study Unknown status NCT01306981 Phase 4 Ranibizumab;Saline
23 Sympathetic Nervous System Inhibition for the Treatment of Diabetic Nephropathy Unknown status NCT01094769 Phase 4 Moxonidine;Placebo
24 Effect of Exenatide on 24h-UAER in Patients With Diabetic Nephropathy: a 24- Week Study Unknown status NCT02690883 Phase 4 Exenatide;Lispro
25 Safety and Efficacy of Shenyankangfu Tablets for Chronic Kidney Disease Unknown status NCT02885857 Phase 4 Shenyan Kangfu Tablet
26 Intensive Medical Treatment for Nephropathy Caused by Type 2 Diabetes With Hypertension Unknown status NCT00407680 Phase 4 Intensive therapy Valsartan,Fluvastatin
27 A Study on the Anti-proteinuric Effects of Pioglitazone in Patients With Type 2 Diabetes. Unknown status NCT00749047 Phase 4 Pioglitazone
28 Pattern Scan Laser System vs Regular Photocoagulation System: Changes in Macular Edema Post Treatment. Unknown status NCT00563628 Phase 4
29 Pattern Scan Laser System vs Regular Photocoagulation System: Changes in Electroretinograms and Contrast Sensitivity Post Treatment. Unknown status NCT00563043 Phase 4
30 Comparison Between ARB and ARB Plus CCB on Incidence of Renal and Cardiovascular Events in Hypertensive ADPKD Patients Unknown status NCT00541853 Phase 4 Candesartan;Candesartan and Cilnidipine;Candesartan plus non-CCB agents
31 Phase IV, Effect of Rennin-Angiotensin System Blockers on Glomerular Filtration Rate in Patients With Hypertension, Type 2 Diabetes With Normoalbuminuria--- A Randomized Controlled Trial Unknown status NCT01500590 Phase 4 Renin-angiotensin system blockers;non-renin angiotensin system blockers
32 Prevention of Renal Complications of Diabetes With Thiamine Unknown status NCT01725412 Phase 4
33 The Reduction of Microalbuminuria in Japanese Hypertensive Subjects With Type 2 Diabetes Mellitus Treated With Valsartan or Amlodipine: Study Design for the Shiga Microalbuminuria Reduction Trial (SMART) Unknown status NCT00202618 Phase 4 Valsartan;Amlodipine
34 Nephropathy in Type 2 Diabetes: Effects of an Intensive Multifactorial Intervention Trial on Cardio-renal Events. Unknown status NCT00535925 Phase 4 current therapy;irbesartan;ramipril;hydrochlorothiazide;furosemide;amlodipine;atenolol;doxazosin;clonidine;insulin;simvastatin;fibrate;erythropoietin;aspirin
35 Predictors of Treatment Response to Aflibercept and Aqueous Cytokine Levels in Patients With Persistent Diabetic Macular Edema Following Treatment With Ranibizumab: An Interventional Prospective Study Unknown status NCT02651168 Phase 4
36 Effect of Aflibercept (Eylea®) in the Management of Bevacizumab (Avastin®) Resistant Diabetic Macular Edema Unknown status NCT02924987 Phase 4 Aflibercept Injection
37 Management of Active and Established Corneal Neovascularisation to Prevent Visual Impairment Unknown status NCT02594423 Phase 4 Bevacizumab
38 The Role of Qutenza (Topical Capsaicin 8%) in Treating Neuropathic Pain From Critical Ischaemia in Patients With End-stage Renal Failure Unknown status NCT01704339 Phase 4 QUTENZA
39 Influence of Nitrates on Bone Remodeling and Endothelial Function in Patients With Type 2 Diabetes Mellitus. Unknown status NCT02011620 Phase 4
40 A Trial of Telmisartan Prevention of Cardiovascular Disease Completed NCT01075698 Phase 4 Non-ARB (standard therapy);ARB (Telmisartan)
41 A 12-months, Randomized, VA-assessor Blinded, Multicenter, Controlled Phase IV Trial to Investigate Noninferiority of Two Treatment Algorithms (Discretion of the Investigator vs. Pro re Nata) of 0.5 mg Ranibizumab in Patients With Visual Impairment Due to Diabetic Macula Edema Completed NCT02366468 Phase 4 ranibizumab 0.5 mg
42 An Open-label, Prospective, Multicentre, Uncontrolled, Proof of Concept Study Assessing the Efficacy of Lucentis (Ranibizumab) Administered by an Individualized "Treat and Extend" Dosing Regimen in Patients With Visual Impairment Due to Diabetic Macular Edema Completed NCT01297569 Phase 4 Ranibizumab
43 A Multicenter, Randomized, Double-blind Non-inferiority Trial to Evaluate the Efficacy and Safety of Entelon® as Compared to Doxium Tab. And Placebo for the Treatment of Nonproliferative Diabetic Retinopathy Completed NCT03962296 Phase 4 Vitis vinifera extract;Calcium Dobesilate;Placebo
44 Diabetic Macula Oedema. A Prospective Randomised Study Comparing the Detailed Functional and Anatomical Changes of Repeated Pan Anti-VEGF Therapy With Ranibizumab Versus Conventional Macular Laser Therapy. Completed NCT01223612 Phase 4 Ranibizumab
45 Intravitreal Bevacizumab for Surgical Treatment of Severe Proliferative Diabetic Retinopathy Completed NCT01025934 Phase 4 Bevacizumab
46 Pain Using Reduced Fluence Parameters in Photocoagulation for Diabetic Retinopathy. Completed NCT00802269 Phase 4
47 Topical Application of Latanoprost in Diabetic Retinopathy Completed NCT01225653 Phase 4 Latanoprost
48 Spironolactone in Diabetic Nephropathy Completed NCT00317954 Phase 4 Spironolactone
49 Evaluation of Diabetic Retinopathy Progression in Subjects With Type 2 Diabetes Mellitus Treated With Insulin Completed NCT00174824 Phase 4 Insulin glargine
50 Dexamethasone Intravitreal Implant (0.7mg) for the Treatment of Persistent Diabetic Macular Edema Following Intravitreal Anti-Vascular Endothelial Growth Factor Therapy Completed NCT02471651 Phase 4 Dexamethasone intravitreal implant (0.7 mg);Intravitreal anti-VEGF injection

Search NIH Clinical Center for Microvascular Complications of Diabetes 5

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Aflibercept
benazepril
Benazepril hydrochloride
candesartan
candesartan cilexetil
Captopril
Enalapril
Enalapril Maleate
Enalaprilat
eprosartan
Eprosartan mesylate
Fosinopril
Fosinopril Sodium
irbesartan
Lisinopril
Losartan
Losartan Potassium
moexipril
Moexipril hydrochloride
olmesartan
Olmesartan medoxomil
Perindopril
Perindopril arginine
Perindopril Erbumine
quinapril
Quinapril hydrochloride
Ramipril
Ranibizumab
telmisartan
trandolapril
valsartan

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cochrane evidence based reviews: diabetic retinopathy

Genetic Tests for Microvascular Complications of Diabetes 5

Genetic tests related to Microvascular Complications of Diabetes 5:

# Genetic test Affiliating Genes
1 Diabetic Retinopathy 29
2 Microvascular Complications of Diabetes 5 29 PON1

Anatomical Context for Microvascular Complications of Diabetes 5

MalaCards organs/tissues related to Microvascular Complications of Diabetes 5:

41
Eye, Endothelial, Retina, Kidney, Testes, Bone, Pituitary
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Microvascular Complications of Diabetes 5:
# Tissue Anatomical CompartmentCell Relevance
1 Eye Outer Nuclear Layer Mature L Cone Cells Affected by disease, potential therapeutic candidate
2 Eye Outer Nuclear Layer Mature M Cone Cells Affected by disease, potential therapeutic candidate
3 Eye Inner Nuclear Layer Mature Muller Glia Cells Affected by disease
4 Eye Outer Nuclear Layer Mature Rod Cells Affected by disease, potential therapeutic candidate
5 Eye Outer Nuclear Layer Mature S Cone Cells Affected by disease, potential therapeutic candidate

Publications for Microvascular Complications of Diabetes 5

Articles related to Microvascular Complications of Diabetes 5:

(show top 50) (show all 21010)
# Title Authors PMID Year
1
Paraoxonase gene cluster is a genetic marker for early microvascular complications in type 1 diabetes. 9 38 8 71
11918623 2002
2
A variant of paraoxonase (PON1) gene is associated with diabetic retinopathy in IDDM. 9 38 8 71
9661650 1998
3
Effects of 5' regulatory-region polymorphisms on paraoxonase-gene (PON1) expression. 8 71
11335891 2001
4
Paraoxonase-1 L55M polymorphism is associated with an abnormal oral glucose tolerance test and differentiates high risk coronary disease families. 71
11889198 2002
5
LL-paraoxonase genotype is associated with a more severe degree of homeostasis model assessment IR in healthy subjects. 71
11788650 2002
6
Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. 71
9011577 1997
7
Progression of diabetic retinopathy during pregnancy in women with type 2 diabetes. 9 38
20225131 2010
8
Sorafenib protects human optic nerve head astrocytes from light-induced overexpression of vascular endothelial growth factor, platelet-derived growth factor, and placenta growth factor. 9 38
20166888 2010
9
Correlation of electroretinography b-wave absolute latency, plasma levels of human basic fibroblast growth factor, vascular endothelial growth factor, soluble fatty acid synthase, and adrenomedullin in diabetic retinopathy. 9 38
19216096 2010
10
Expression of stromal cell-derived factor-1 in diabetic retinopathy. 9 38
20497701 2010
11
Plasma and aqueous humor angiotensin-converting enzyme levels in patients with diabetic retinopathy. 9 38
20373882 2010
12
Pleiotropic effects of YC-1 selectively inhibit pathological retinal neovascularization and promote physiological revascularization in a mouse model of oxygen-induced retinopathy. 9 38
20008515 2010
13
Diabetic retinopathy: An update on treatment. 9 38
20193825 2010
14
Oxidative damage of mitochondrial DNA in diabetes and its protection by manganese superoxide dismutase. 9 38
20088710 2010
15
Retinal overexpression of angiopoietin-2 mimics diabetic retinopathy and enhances vascular damages in hyperglycemia. 9 38
19238311 2010
16
Protein kinase C beta (PRKCB1) and pigment epithelium derived factor (PEDF) gene polymorphisms and diabetic retinopathy in a south Indian cohort. 9 38
20141354 2010
17
Masked hypertension, nocturnal blood pressure and retinopathy in normotensive patients with type 1 diabetes. 9 38
19926157 2010
18
Correlation of vascular endothelial growth factor with chemokines in the vitreous in diabetic retinopathy. 9 38
20142713 2010
19
Sustained regression of florid diabetic retinopathy in a patient with Donohue syndrome (leprechaunism). 9 38
19882513 2010
20
Genetic polymorphisms in genes encoding antioxidant enzymes are associated with diabetic retinopathy in type 1 diabetes. 9 38
19752172 2009
21
Common sequence variation in the VEGFA gene predicts risk of diabetic retinopathy. 9 38
19553626 2009
22
Vascular endothelial growth factor-A: a multifunctional molecular player in diabetic retinopathy. 9 38
19646547 2009
23
The anti-angiogenic isoforms of VEGF in health and disease. 9 38
19909248 2009
24
Subconjunctivally implantable hydrogels with degradable and thermoresponsive properties for sustained release of insulin to the retina. 9 38
19709741 2009
25
Effects of trace elements on albumin and lipoprotein glycation in diabetic retinopathy. 9 38
19838431 2009
26
Polymorphism of the manganese superoxide dismutase gene but not of vascular endothelial growth factor gene is a risk factor for diabetic retinopathy. 9 38
19628492 2009
27
Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study. 9 38
19526210 2009
28
A systematic meta-analysis of genetic association studies for diabetic retinopathy. 9 38
19587357 2009
29
Effect of serum cytokines and VEGF levels on diabetic retinopathy and macular thickness. 9 38
19784389 2009
30
Differences in retinal neovascular tissue and vitreous humour in patients with type 1 and type 2 diabetes. 9 38
19304585 2009
31
Specific medical intervention for diabetic retinopathy. 9 38
19380207 2009
32
Systemic administration of HMG-CoA reductase inhibitor protects the blood-retinal barrier and ameliorates retinal inflammation in type 2 diabetes. 9 38
19254713 2009
33
Production of scFv antibody fragments from a hybridoma with functional activity against human vascular endothelial growth factor. 9 38
19445630 2009
34
Diabetic retinopathy, PAI-1 4G/5G and -844G/A polymorphisms, and changes in circulating PAI-1 levels in Tunisian type 2 diabetes patients. 9 38
19419896 2009
35
Diabetic retinopathy in permanent neonatal diabetes due to Kir6.2 gene mutations: the results of a minimum 2-year follow-up after the transfer from insulin to sulphonylurea. 9 38
19538247 2009
36
Treating diabetic retinopathy by inhibiting growth factor pathways. 9 38
19337953 2009
37
Modulation of thrombospondin 1 and pigment epithelium-derived factor levels in vitreous fluid of patients with diabetes. 9 38
19365032 2009
38
Diabetic retinopathy is associated with insulin resistance and cardiovascular autonomic dysfunction in type 2 diabetic patients. 9 38
19262488 2009
39
Single nucleotide polymorphisms of vascular endothelial growth factor gene intron 2 are markers for early progression of diabetic retinopathy in Japanese with type 1 diabetes. 9 38
19263526 2009
40
Low plasma basic fibroblast growth factor is associated with laser photocoagulation treatment in adult type 2 diabetes mellitus from the Veterans Affairs Diabetes Trial. 9 38
19217457 2009
41
Ganglioside GM3 inhibits VEGF/VEGFR-2-mediated angiogenesis: direct interaction of GM3 with VEGFR-2. 9 38
18974200 2009
42
[Role of vascular endothelial growth factor in the pathogenesis of diabetic retinopathy]. 9 38
19517837 2009
43
Activities of angiotensin-converting enzymes ACE1 and ACE2 and inhibition by bioactive peptides in porcine ocular tissues. 9 38
19232015 2009
44
Impact of variants in the VEGF gene on progression of proliferative diabetic retinopathy. 9 38
18709380 2009
45
Analysis of three pigment epithelium-derived factor gene polymorphisms in patients with exudative age-related macular degeneration. 9 38
19223990 2009
46
Regulation of pigment epithelium-derived factor production and release by retinal glial (Müller) cells under hypoxia. 9 38
18676622 2008
47
[Proliferative diabetic retinopathy inauguring gestational diabetes]. 9 38
18514611 2008
48
Vasoinhibins: novel inhibitors of ocular angiogenesis. 9 38
18544641 2008
49
Pigment epithelium-derived factor mitigates inflammation and oxidative stress in retinal pericytes exposed to oxidized low-density lipoprotein. 9 38
18586837 2008
50
[Positive effects of angiotensin [corrected] receptor blockers on the course of microvascular complications of diabetes mellitus]. 9 38
18830032 2008

Variations for Microvascular Complications of Diabetes 5

ClinVar genetic disease variations for Microvascular Complications of Diabetes 5:

6
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 PON1 NM_000446.7(PON1): c.163T> A (p.Leu55Met) single nucleotide variant risk factor rs854560 7:94946084-94946084 7:95316772-95316772

Expression for Microvascular Complications of Diabetes 5

Search GEO for disease gene expression data for Microvascular Complications of Diabetes 5.

Pathways for Microvascular Complications of Diabetes 5

Pathways related to Microvascular Complications of Diabetes 5 according to KEGG:

37
# Name Kegg Source Accession
1 AGE-RAGE signaling pathway in diabetic complications hsa04933
2 HIF-1 signaling pathway hsa04066
3 Renin-angiotensin system hsa04614

Pathways related to Microvascular Complications of Diabetes 5 according to GeneCards Suite gene sharing:

(show top 50) (show all 54)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.73 VEGFA TEK PRKCB PGF NOS3 KDR
2
Show member pathways
13.56 TEK PRKCB PGF NOS3 KDR IGF1
3
Show member pathways
13.55 VEGFA TEK PGF KDR INS IGF1
4
Show member pathways
13.42 TEK PRKCB PGF NOS3 KDR IGF1
5
Show member pathways
13.34 VEGFA TEK SERPINE1 PRKCB NOS3 IGF1
6
Show member pathways
13.33 TEK PRKCB PGF KDR IGF1 FLT1
7
Show member pathways
13.32 TEK PRKCB PGF KDR IGF1 FLT1
8
Show member pathways
13.26 VEGFA TEK PRKCB PGF NOS3 KDR
9
Show member pathways
13.06 PRKCB PGF KDR IGF1 FLT1 FGF2
10
Show member pathways
13.02 PRKCB PGF KDR INS IGF1 FLT1
11
Show member pathways
12.92 VEGFA PRKCB PGF KDR IGF1 FLT1
12
Show member pathways
12.86 VEGFA TEK PGF NOS3 KDR INS
13 12.84 VEGFA PRKCB PGF IGF1 FGF2
14
Show member pathways
12.73 PRKCB PGF KDR IGF1 FLT1 FGF2
15
Show member pathways
12.7 VEGFA PRKCB KDR IGF1 FGF2
16
Show member pathways
12.67 VEGFA PRKCB NOS3 KDR ICAM1
17 12.62 VEGFA TEK PRKCB PGF KDR INS
18
Show member pathways
12.53 PRKCB KDR INS IGF1 FLT1
19
Show member pathways
12.5 VEGFA TEK PRKCB PGF KDR INS
20
Show member pathways
12.44 PRKCB NOS3 KDR FLT1
21
Show member pathways
12.43 VEGFA PRKCB NOS3 KDR ICAM1
22
Show member pathways
12.43 VEGFA PRKCB PGF NOS3 KDR FLT1
23
Show member pathways
12.42 TEK PGF KDR IGF1 FLT1 FGF2
24
Show member pathways
12.39 VEGFA KDR FLT1 FGF2
25
Show member pathways
12.33 SERPINE1 INS ICAM1 ALB
26 12.33 VEGFA PRKCB KDR IGF1 FGF2
27
Show member pathways
12.29 PRKCB PGF KDR IGF1 FLT1 FGF2
28
Show member pathways
12.19 VEGFA PRKCB NOS3 KDR FLT1 FGF2
29 12.14 TEK KDR FLT1 FGF2 ANGPT2